Busca un médico

Jeremy T. Larsen, M.D.

  1. Hematologist
  2. Internist
  3. Oncologist

Publicaciones

  1. Dimopoulos MA, Migkou M, Bhutani M, Ailawadhi S, Kalff A, Walcott FL, Pore N, Brown M, Wang F, Cheng LI, Kagiampakis I, Williams M, Kinneer K, Wu Y, Jiang Y, Kubiak RJ, Zonder JA, Larsen J, Sirdesai S, Yee AJ, Kumar S. Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. Leuk Lymphoma. 2024 Oct 15; 1-12 [Epub ahead of print]
    View PubMed
  2. Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Jun; 23 (6):456-462 Epub 2023 Mar 07
    View PubMed
  3. Fonseca R, Arribas M, Wiedmeier-Nutor JE, Kusne YN, Gonzalez Velez M, Kosiorek HE, Butterfield RDJ, Kirsch IR, Mikhael JR, Stewart AK, Reeder C, Larsen J, Bergsagel PL, Fonseca R. Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023 May 26; 13 (1):87
    View PubMed
  4. Bansal R, Baksh M, Larsen JT, Hathcock MA, Dingli D, Stewart AK, Kapoor P, Kourelis T, Hayman SR, Warsame RM, Fonseca R, Bergsagel PL, Ailawadhi S, Kumar SK, Lin Y. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer J. 2023 Apr 5; 13 (1):47 Epub 2023 Apr 05
    View PubMed
  5. Fonseca R, Arribas M, Wiedmeier-Nutor JE, Kusne YN, Gonzalez Velez M, Kosiorek HE, Butterfield RDJ, Kirsch IR, Mikhael JR, Stewart AK, Reeder C, Larsen J, Bergsagel PL, Fonseca R. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023 Mar 6; 13 (1):32 Epub 2023 Mar 06
    View PubMed
  6. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023 Jan; 98 (1):49-55 Epub 2022 Oct 24
    View PubMed
  7. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan AA, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. Blood. 2022 Nov 3; 140 (18):1997-2000
    View PubMed
  8. Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson PG, Facon T, Weisel K, Larsen JT, Minnema MC, Abdallah AO, Badros AZ, Knop S, Stadtmauer EA, Cheng Y, Amatangelo M, Chen M, Nguyen TV, Amin A, Peluso T, van de Donk NWCJ. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol. 2022 Nov; 9 (11):e822-e832 Epub 2022 Oct 06
    View PubMed
  9. Abeykoon JP, Vaxman J, Patel SV, Kumar S, Malave GC, Young KS, Ailawadhi S, Larsen JT, Dispenzieri A, Muchtar E, Gonsalves WI, Kourelis T, Leung N, Warsame R, Go RS, Bergsagel L, Lacy MQ, Rajkumar SV, Gertz MA, Kapoor P. Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. Br J Haematol. 2022 Oct; 199(1):95-99. Epub 2022 Jun 13.
    View PubMed
  10. Muchtar E, Gertz MA, LaPlant BR, Buadi FK, Leung N, O'Brien P, Bergsagel PL, Fonder A, Hwa YL, Hobbs M, Helgeson DK, Bradt EE, Gonsalves W, Lacy MQ, Kapoor P, Siddiqui M, Larsen JT, Warsame R, Hayman SR, Go RS, Dingli D, Kourelis TV, Dispenzieri A, Rajkumar SV, Kumar SK. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. Blood Adv. 2022 Sep 27; 6 (18):5429-5435
    View PubMed
  11. Razonable RR, O'Horo JC, Challener DW, Arndt L, Arndt RF, Clune CG, Culbertson TL, Hall ST, Heyliger A, Jackson TA, Kennedy BD, Larsen J, Hanson SN, Sweeten PW, Tulledge-Scheitel SM, Ganesh R. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019. Mayo Clin Proc. 2022 Sep; 97 (9):1641-1648 Epub 2022 June 23
    View PubMed
  12. Munoz J, Larsen J. Calvarium indentations in multiple myeloma and CAR T-cell therapy. Lancet. 2022 Jul 30; 400 (10349):391
    View PubMed
  13. Singh A, Al-Kali A, Begna KH, Litzow MR, Larsen JT, Sher T, Abdelmagid MG, Farrukh F, Reichard KK, Gangat N, Pardanani A, Tefferi A. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. Am J Hematol. 2022 May; 97 (5):630-637 Epub 2022 Feb 22
    View PubMed
  14. Christensen JH, Zhang F, Coombes B, Cairns M, Cunningham J, Curtis D, Roth J, Xu W, Davis OSP, Martinez ED, Mitchell K, Larsen JT, Zhao H, Wilson P, Klein J, Sharma S, Meyer P, Morgan T, Mullins N, Kang J, Campos AI, Coleman JRI, Edwards AC, Galfalvy H, Levey DF, Lori A, Shabalin A, Starnawska A, Su MH, Watson HJ, Adams M, Awasthi S, Gandal M, Hafferty JD, Hishimoto A, Kim M, Okazaki S, Otsuka I, Ripke S, Ware EB, Bergen AW, Berrettini WH, Bohus M, Brandt H, Chang X, Chen WJ, Chen HC, Crawford S, Crow S, DiBlasi E, Duriez P, Fernandez-Aranda F, Fichter MM, Gallinger S, Glatt SJ, Gorwood P, Guo Y, Hakonarson H, Halmi KA, Hwu HG, Jain S, Jamain S, Jimenez-Murcia S, Johnson C, Kaplan AS, Kaye WH, Keel PK, Kennedy JL, Klump KL, Li D, Liao SC, Lieb K, Lilenfeld L, Liu CM, Magistretti PJ, Marshall CR, Mitchell JE, Monson ET, Myers RM, Pinto D, Powers A, Ramoz N, Roepke S, Rozanov V, Scherer SW, Schmahl C, Sokolowski M, Strober M, Thornton LM, Treasure J, Tsuang MT, Witt SH, Woodside DB, Yilmaz Z, Zillich L, Adolfsson R, Agartz I, Air TM, Alda M, Alfredsson L, Andreassen OA, Anjorin A, Appadurai V, Soler Artigas M, Van der Auwera S, Azevedo MH, Bass N, Bau CHD, Baune BT, Bellivier F, Berger K, Biernacka JM, Bigdeli TB, Binder EB, Boehnke M, Boks MP, Bosch R, Braff DL, Bryant R, Budde M, Byrne EM, Cahn W, Casas M, Castelao E, Cervilla JA, Chaumette B, Cichon S, Corvin A, Craddock N, Craig D, Degenhardt F, Djurovic S, Edenberg HJ, Fanous AH, Foo JC, Forstner AJ, Frye M, Fullerton JM, Gatt JM, Gejman PV, Giegling I, Grabe HJ, Green MJ, Grevet EH, Grigoroiu-Serbanescu M, Gutierrez B, Guzman-Parra J, Hamilton SP, Hamshere ML, Hartmann A, Hauser J, Heilmann-Heimbach S, Hoffmann P, Ising M, Jones I, Jones LA, Jonsson L, Kahn RS, Kelsoe JR, Kendler KS, Kloiber S, Koenen KC, Kogevinas M, Konte B, Krebs MO, Landen M, Lawrence J, Leboyer M, Lee PH, Levinson DF, Liao C, Lissowska J, Lucae S, Mayoral F, McElroy SL, McGrath P, McGuffin P, McQuillin A, Medland SE, Mehta D, Melle I, Milaneschi Y, Mitchell PB, Molina E, Morken G, Mortensen PB, Muller-Myhsok B, Nievergelt C, Nimgaonkar V, Nothen MM, O'Donovan MC, Ophoff RA, Owen MJ, Pato C, Pato MT, Penninx BWJH, Pimm J, Pistis G, Potash JB, Power RA, Preisig M, Quested D, Ramos-Quiroga JA, Reif A, Ribases M, Richarte V, Rietschel M, Rivera M, Roberts A, Roberts G, Rouleau GA, Rovaris DL, Rujescu D, Sanchez-Mora C, Sanders AR, Schofield PR, Schulze TG, Scott LJ, Serretti A, Shi J, Shyn SI, Sirignano L, Sklar P, Smeland OB, Smoller JW, Sonuga-Barke EJS, Spalletta G, Strauss JS, Swiatkowska B, Trzaskowski M, Turecki G, Vilar-Ribo L, Vincent JB, Volzke H, Walters JTR, Shannon Weickert C, Weickert TW, Weissman MM, Williams LM, Wray NR, Zai CC, Ashley-Koch AE, Beckham JC, Hauser ER, Hauser MA, Kimbrel NA, Lindquist JH, McMahon B, Oslin DW, Qin X, Agerbo E, Borglum AD, Breen G, Erlangsen A, Esko T, Gelernter J, Hougaard DM, Kessler RC, Kranzler HR, Li QS, Martin NG, McIntosh AM, Mors O, Nordentoft M, Olsen CM, Porteous D, Ursano RJ, Wasserman D, Werge T, Whiteman DC, Bulik CM, et al, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium//Bipolar Disorder Working Group of the Psychiatric Genomics Consortium//Eating Disorders Working Group of the Psychiatric Genomics Consortium//German Borderline Genomics Consortium//MVP Suicide Exemplar Workgroup//VA Mi, Mann JJ. Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biol Psychiatry. 2022 Feb 1; 91 (3):313-327 Epub 2021 Sept 09
    View PubMed
  15. Abeykoon JP, Zanwar S, Ansell SM, Muchtar E, He R, Greipp PT, King RL, Ailawadhi S, Paludo J, Larsen JT, Habermann TM, Inwards D, Go RS, Thanarajasingam G, Buadi F, Dispenzieri A, Thompson CA, Witzig TE, Lacy M, Gonsalves W, Nowakowski GS, Dingli D, Rajkumar SV, Kyle RA, Sher T, Roy V, Rosenthal A, Chanan-Khan AA, Reeder C, Gertz MA, Kumar S, Kapoor P. Assessment of fixed-duration therapies for treatment-naive Waldenstrom macroglobulinemia. Am J Hematol. 2021 Aug 1; 96 (8):945-953 Epub 2021 May 22
    View PubMed
  16. Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, Lacy MQ, Dingli D, Ailawadhi S, Bergsagel PL, Fonseca R, Hayman SR, Kapoor P, Grogan M, Abou Ezzeddine OF, Rosenthal JL, Mauermann M, Siddiqui M, Gonsalves WI, Kourelis TV, Larsen JT, Reeder CB, Warsame R, Go RS, Murray DL, McPhail ED, Dasari S, Jevremovic D, Kyle RA, Lin Y, Lust JA, Russell SJ, Hwa YL, Fonder AL, Hobbs MA, Rajkumar SV, Roy V, Sher T. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc. 2021 Jun; 96(6):1546-1577.
    View PubMed
  17. Carnahan MB, Larsen JT, Conley CR, Yang M. Concurrent Liver and Mesentery Primary Extraosseous Multiple Myeloma on 18F-FDG PET/CT. Clin Nucl Med. 2021 Feb 1; 46 (2):e100-e102
    View PubMed
  18. Mountjoy L, Sebastian S, Jain T, Hilal T, Gonzalez-Velez M, Girardo M, Ahmann G, Larsen J, Bergsagel L, Fonseca R. Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity. Leukemia 2020 Nov; 34 (11):3060-3063 Epub 2020 June 05
    View PubMed
  19. Bonolo de Campos C, Meurice N, Petit JL, Polito AN, Zhu YX, Wang P, Bruins LA, Wang X, Lopez Armenta ID, Darvish SA, Ahmann GJ, Henderson KJ, Tian S, Kruse JJ, Stewart WM, Larsen JT, Reeder CB, Dingli D, Kapoor P, Kumar SK, Fonseca R, Bergsagel PL, Braggio E, Stewart AK. "Direct to Drug" screening as a precision medicine tool in multiple myeloma. Blood Cancer J. 2020 May 11; 10 (5):54
    View PubMed
  20. Restrepo VJ, Shah VS, Jain T, Larsen JT, Narayanasamy H, Arsanjani R, Hardaway BW, Mookadam F, Larsen C. Cardiovascular outcomes following bortezomib reinitiation after congestive heart failure diagnosis in multiple myeloma Journal Of The American College Of Cardiology. 2020 Mar 24; 75(11):723. Epub 1900 Jan 01.
  21. Larsen JT. Think Twice: Doubling Back to Tandem Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma with Extramedullary Disease. Biol Blood Marrow Transplant 2019 Nov; 25 (11):e317-e318 Epub 2019 Sept 19
    View PubMed
  22. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019 Mar; 54 (3):353-367 Epub 2018 July 09
    View PubMed
  23. Larsen JT, Leonard FD. Symptomatic Hypoalbuminemia as an Indication for Treatment of Waldenstrom Macroglobulinemia: A Case Report and Review of the Literature. Case Rep Hematol. 2019; 2019:1929124 Epub 2019 Oct 03
    View PubMed
  24. Jain T, Kosiorek HE, Kung ST, Shah VS, Dueck AC, Gonzalez-Calle V, Luft S, Reeder CB, Adams R, Noel P, Larsen JT, Mikhael J, Bergsagel L, Stewart AK, Fonseca R. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2018 Jul; 18 (7):486-492.e1 Epub 2018 May 04
    View PubMed
  25. Larsen JT, Shanafelt TD, Leis JF, LaPlant B, Call T, Pettinger A, Hanson C, Erlichman C, Habermann TM, Reeder C, Nikcevich D, Bowen D, Conte M, Boysen J, Secreto C, Lesnick C, Tschumper R, Jelinek D, Kay NE, Ding W. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. Am J Hematol. 2017 Aug; 92 (8):759-763 Epub 2017 June 01
    View PubMed
  26. Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, Go R, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 2016 Jul 29; 6 (7):e454 Epub 2016 July 29
    View PubMed
  27. Nathwani N, Larsen JT, Kapoor P. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Curr Hematol Malig Rep. 2016 Apr; 11 (2):127-36
    View PubMed
  28. Larsen JT, Kumar S. Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. Rare Cancers Ther. 2015; 3:47-68 Epub 2015 Aug 28
    View PubMed
  29. Kaufman GP, Larsen JT, Elliott MA, Howard MT. Pancytopenia with focal serous atrophy (gelatinous transformation) of the bone marrow. J Hematopathol. 2014 May; 7(2):91-2.
  30. Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Leuk Lymphoma. 2013 Aug; 54 (8):1713-8 Epub 2012 Dec 31
    View PubMed
  31. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013 Apr; 27 (4):941-6 Epub 2012 Oct 16
    View PubMed
  32. Larsen JT, Chee CE, Lust JA, Greipp PR, Rajkumar SV. Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood. 2011 Sep 8; 118 (10):2702-7 Epub 2011 July 12
    View PubMed
PST-20347938